District leaders can now easily find state-specific information and resources to support the CLSD planning and application process

IRVING, Texas, Sept. 28, 2026 /PRNewswire/ -- As school districts look for ways to strengthen literacy instruction and family engagement to make the most of available funding, Just Right Reader has launched a new online informational hub to help district leaders navigate the Comprehensive Literacy State Development (CLSD) grant program. The hub brings together valuable information on CLSD requirements, state funding opportunities, allowable uses, evidence requirements, and application considerations in one easily-accessible location.

"CLSD funding gives district leaders an important opportunity to make strategic investments in literacy that reflect the needs of their students and educators," said Sara Rich, founder and CEO of Just Right Reader. "Our new informational hub gives leaders a starting point to explore funding opportunities, understand state-specific priorities, and develop comprehensive literacy plans that support student achievement and family engagement."

CLSD grants provide districts with the opportunity to develop and implement comprehensive, evidence-based literacy programs that improve outcomes for students from birth through Grade 12, with particular attention to students who are most underserved. The grants require districts to invest funding in evidence-based literacy activities, strategies, and interventions, as defined by the Every Student Succeeds Act (ESSA).

On the informational hub, district leaders will find:

- State-specific information: Links and resources to help identify CLSD opportunities, requirements, and timelines in their state.

- Grant requirements and evidence: An overview of CLSD's evidence requirements and the role of evidence-based literacy practices in funding decisions.

- Allowable uses: Information about how CLSD funding can support literacy efforts across areas such as early literacy, K-5 foundational literacy, adolescent literacy, intervention, professional development, and family engagement.

- Application planning: Access to guidance to support CLSD applications, including aligning resources with district priorities, developing supporting grant language, planning budgets and reviewing applications before submission.

- Additional resources: Answers to FAQs, as well as links to federal CLSD information, federal grant requirements, U.S. Department of Education guidance on evidence-based education, and more.

To access the CLSD informational hub, visit https://justrightreader.com/pages/clsd-grant.

About Just Right Reader

At Just Right Reader, we accelerate reading achievement in school, at home, and everywhere through Birth–12th-grade literacy programs, evidence-based Science of Reading resources, an extensive family engagement platform, and a commitment to personalized learning. With a library of 1,000+ English and Spanish books, students get the explicit, systematic practice needed to become stronger, more confident readers.

Visit www.justrightreader.com for more information.

SOURCE Just Right Reader

Share this article

FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a study showing that its TissueCypher® Barrett's Esophagus Test helped guide risk-aligned management decisions for patients with non-dysplastic Barrett's esophagus (NDBE). In the study, clinicians changed their management recommendations 90% of the time after receiving TissueCypher results, including escalating management for all patients with intermediate- or high-risk results and de-escalating management for 84% of those with low-risk results.

The study, titled "The Tissue Systems Pathology Test Guides Physician Recommendations for Patients With Non-Dysplastic Barrett's Esophagus: A Case Series From a Gastrointestinal Surgery Center," was published in Foregut: The Journal of the American Foregut Society and is available here.

"All patients in this study had the same non-dysplastic Barrett's diagnosis, but TissueCypher showed that their risk of progression differed," said study author Caitlin C. Houghton, M.D., board-certified foregut surgeon at Keck Medicine of the University of Southern California (USC) in Los Angeles. "The test results helped us tailor management to each patient's individual risk — whether that meant closer surveillance or endoscopic eradication therapy for patients with intermediate- or high-risk results, or a longer surveillance interval for those with low-risk results. Ultimately, TissueCypher can help us detect patients at increased risk who may benefit from earlier surveillance or treatment and avoid unnecessary procedures for patients at lower risk."

Barrett's esophagus (BE) is a precancerous condition that can progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Patients with NDBE represent the majority of those undergoing surveillance for BE and are generally considered to have a low risk of progression. However, traditional clinicopathologic factors alone may not reliably distinguish the subset of patients with NDBE who are at elevated risk of progression, highlighting the need for more precise risk stratification. To assess TissueCypher's clinical utility in this population, the study evaluated 30 patients with NDBE who received testing as part of their clinical care at Keck Medical Center of USC.

Key Study Findings:

- TissueCypher identified higher-risk patients within NDBE: The test classified 17% of patients as intermediate or high risk for progression to HGD/EAC within five years and 83% of patients as low risk.

- Intermediate- or high-risk results supported escalated management: Management plans were escalated for all patients with intermediate- or high-risk TissueCypher results, including endoscopic eradication therapy for four patients and shorter-interval surveillance for one.

- Lower-risk results supported de-escalated management: Management was de-escalated for 84% of patients with low-risk TissueCypher results, including extending surveillance intervals or no longer recommending endoscopic eradication therapy.

- Test results changed management or increased confidence: TissueCypher results changed management recommendations or increased physicians' confidence in their plans for 97% of patients.

Findings from the study were also presented on Sept. 27 at the American College of Surgeons Clinical Congress 2026 in Washington, D.C.

Presentation details:

- Title: The Tissue Systems Pathology Test Impacts Clinician-recommended Management Decisions for Patients with Non-dysplastic Barrett's Esophagus

- Presenter: Katie M. Galvin, M.D., Keck School of Medicine of USC

- Session: QS101-1 | Quick-Shots I - Station 1: Bariatric/Foregut

About TissueCypher Barrett's Esophagus Test

TissueCypher is a precision medicine test designed and extensively validated to predict a patient's personalized risk of progression from Barrett's esophagus (BE) to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC). Indicated for patients with non-dysplastic BE, indefinite for dysplasia or with low-grade dysplasia, TissueCypher's five-year risk assessment is designed to help physicians tailor care to each patient's risk of developing HGD or EAC.

Backed by more than 17 peer-reviewed publications and studied in biopsies from more than 8,000 patients, TissueCypher has been shown to be the strongest independent predictor of progression compared with traditional histopathological risk assessment. Using an AI-derived spatialomics approach, the test identifies molecular signatures that often precede the development of dysplasia, which can enable earlier identification, treatment, and management of patients at increased risk of cancer. TissueCypher is designed to integrate seamlessly into routine endoscopic practice by analyzing standard esophageal pinch biopsies, delivering actionable insights without requiring additional procedures. Learn more at CastleBiosciences.com/TissueCypher.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. With a primary focus in dermatologic and gastroenterological disease, we develop personalized, clinically actionable solutions that help improve disease management and patient outcomes.

We put people first—empowering patients and clinicians and informing care decisions through rigorous science and advanced molecular tests that support more confident treatment planning. To learn more, visit www.CastleBiosciences.com and connect with us on LinkedIn, Instagram, Facebook and X.

DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, AdvanceAD-Tx, TissueCypher, Esopredict, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: TissueCypher's ability to (i) predict a patient's personalized risk of progression from Barrett's esophagus to high-grade dysplasia or esophageal adenocarcinoma, (ii) help clinicians tailor surveillance and management decisions to each patient's individual risk profile, (iii) enable earlier identification and management of patients at increased risk of cancer, and (iv) help reduce uncertainty for patients. The words "believe," "can," "may" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, and our subsequent Quarterly Reports on Form 10-Q, each as filed or to be filed with the SEC, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.

Investor Contact:

Camilla Zuckero

[email protected]

Media Contact:

Allison Marshall

[email protected]

SOURCE Castle Biosciences, Inc.

Share this article

Move delivers cloud, AI and API-enabled payables and receivables finance, in its first phase, including native risk distribution that can be integrated with Finastra's award-winning Trade Innovation and Loan IQ applications.

MIAMI, Sept. 28, 2026 /PRNewswire/ -- Today at Sibos 2026, Finastra announced Finastra Supply Chain Finance (SCF), a solution designed to help banks scale working capital programs faster and unlock growth. Integrated with Finastra's Trade Innovation and Loan IQ platforms through the Nexus API suite, SCF enables banks to deliver connected trade, lending and supply chain finance services while accelerating time to market.

Finastra SCF is an end-to-end platform supporting buyer and supplier acquisition, onboarding, fulfillment, servicing, risk management, and secondary market distribution. The solution delivers straight-through processing, connects with ERP systems and trade ecosystem partners through the Nexus API suite, and provides a rich data foundation for decisioning and portfolio management. Built on a cloud-native architecture and available through flexible deployment models, from on-premise to SaaS, it delivers the resiliency and scalability of Finastra's market-leading solutions used by thousands of banks globally.

The launch represents the latest phase of Finastra's continued investment in Trade Innovation and Loan IQ, extending the company's vision for a connected working capital ecosystem that enables banks to manage trade, lending and supply chain finance products through a unified commercial and risk management framework.

How Finastra SCF will help banks transform supply chain finance:

- Faster time to market – Accelerate product launches through pre-built connectivity to corporate systems, ecosystem partners and existing Trade Innovation and Loan IQ integrations.

- Holistic working capital management – Manage limits, exposures and data across trade finance, letters of credit, guarantees, loans and supply chain finance from a unified platform.

- Automated risk distribution – Distribute assets seamlessly through native secondary market capabilities with automated pricing, limit management and reconciliation.

- Enhanced risk management – Improve control through AI-enabled fraud detection, compliance screening and eligibility monitoring embedded within operational workflows.

- Scale efficiently – Support thousands of counterparties and millions of invoices with straight-through processing, real-time servicing and high-performance architecture.

Future releases will expand capabilities to include purchase order (PO) finance, pre- to post-shipment finance, inventory finance, distributor finance, and additional working capital solutions.

Expert perspective: Driving supply chain finance growth

"Banks are looking for ways to bring new working capital solutions to market faster to capture new revenue streams delivered through STP journeys, and lower costs, while addressing operational risks and regulatory complexity," said Vinay Mendonca, Head of Product, Trade Supply Chain Finance and Corporate Channels at Finastra. "By combining new supply chain finance capabilities with Trade Innovation and Loan IQ, we're enabling banks to take a more connected approach to working capital. This launch marks an important milestone in the evolution of our Trade Innovation platform as we look to bring more API, AI and cloud-led innovation to the market, leveraging our deep expertise in the trade domain, to help institutions innovate and grow."

Trade Innovation is a digital trade finance platform that helps institutions automate workflows, reduce risk, and improve working capital efficiency. As part of Finastra's investment strategy, the platform is evolving into a modular, cloud-ready and API-first ecosystem that enables banks to scale operations, integrate seamlessly and deliver connected trade and lending experiences.

To learn more, visit: Trade Innovation Trade Finance Software | Finastra

Visit Finastra at Sibos on booth #H015.

For further information please contact:

Caroline Duff

Global PR Director

T: +44 (0)7917 613586

E: [email protected]

finastra.com

About Finastra

Finastra provides the mission-critical software that powers thousands of financial institutions in more than 100 countries - including many of the world's leading banks. Its technology helps financial institutions move money as well as extend and service loans that financial services businesses and consumers rely on every day. Backed by Vista Equity Partners, Finastra combines deep financial services expertise with secure, reliable and scalable technology to help customers modernize operations, accelerate innovation, and grow their businesses in a rapidly evolving industry. Visit Finastra or follow Finastra on LinkedIn.

SOURCE Finastra

Share this article

BRIXMOR PROPERTY GROUP & EVERVIEW PARTNERS TO ACQUIRE SLATE GROCERY REIT FOR $2.34 BILLION

- Brixmor to Acquire 23 Grocery-Anchored Shopping Centers in Existing Markets for $636 Million –

- Capital Efficient Strategic Joint Venture with Everview Partners to Acquire an Additional 92 Centers for $1.71 Billion -

- Provides Immediate Earnings Accretion to Brixmor and Leverages Brixmor's Best-in-Class Operating Platform at Scale –

NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Brixmor Property Group Inc. (NYSE: BRX) ("Brixmor") and Everview Partners ("Everview") announced today they have entered into definitive agreements to acquire Slate Grocery REIT in a transaction valued at $2.34 billion. Under the terms of the transaction and joint venture agreements, Brixmor will effectively acquire a portfolio of 23 grocery-anchored shopping centers (the "Brixmor Portfolio") aggregating approximately three million square feet for $636 million, and a newly formed institutional joint venture between Brixmor and affiliates of Everview Partners will acquire the remaining 92 assets (the "Joint Venture Portfolio") for $1.71 billion. Additionally, a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) will act as a strategic investor alongside Everview in the transaction. The 23-asset portfolio Brixmor is acquiring is approximately 96% leased and located entirely within Brixmor's existing operating footprint, predominantly across Florida, Georgia, and the Carolinas.

"This immediately accretive transaction is directly aligned with our growth strategy, adding 23 grocery-anchored centers in markets we know well, with long-standing grocer relationships we plan to grow, while further leveraging our operating platform in a capital efficient joint venture with Everview. Across both the wholly owned and joint venture assets, we see meaningful embedded value through below-market rents and a robust pipeline of remerchandising, redevelopment, and outparcel opportunities. We believe our extensive retailer relationships and proven execution capabilities will position us to unlock that value and generate meaningful cash flow growth over time," commented Brian T. Finnegan, Brixmor's Chief Executive Officer and President. "We are pleased to partner with Everview and look forward to leveraging our combined strengths to capitalize on the significant opportunities across this portfolio. We'd also like to thank the Special Committee of Slate Grocery REIT for their diligence throughout this process, which we believe resulted in a strong outcome for all parties involved."

Billy Rahm, Everview's Founder and Chief Executive Officer, stated, "This transaction reflects our conviction in grocery-anchored, open-air retail, which we expect will continue to benefit from limited new supply and durable tenant demand. We believe the portfolio is a high-quality collection of centers in attractive markets with meaningful embedded upside. We are excited to be acquiring it alongside Brixmor, whose strong operating platform, retailer relationships, and redevelopment capability make them a great partner."

Under the terms of the applicable transaction and joint venture agreements:

- Brixmor will acquire 23 grocery-anchored shopping centers (representing a 100% interest in 22 centers and a 50% interest in one center) aggregating approximately three million square feet and located entirely within Brixmor's existing operating footprint, predominantly across Florida, Georgia, and the Carolinas.

- Brixmor will hold a 20% common equity interest and Everview will hold an 80% common equity interest in 92 shopping centers aggregating approximately 12 million square feet. Brixmor will also serve as the asset manager, property manager, and leasing representative for the Joint Venture Portfolio. Brixmor will also make a preferred equity investment of approximately $174 million in the joint venture, which will generate a 9% dividend.

- The transaction, which is not subject to any financing conditions, has been approved by Brixmor's Board of Directors and Slate's Board of Trustees and is expected to close in the first quarter of 2027, subject to the receipt of approval of Slate unitholders and satisfaction of other customary closing conditions.

Concurrent with the issuance of this release, Brixmor filed a Form 8-K with the SEC describing the relevant agreements in more detail.

The transaction strengthens Brixmor's strategic position and long-term growth prospects by:

- Adding highly complementary assets to Brixmor's existing portfolio: The Brixmor Portfolio is 100% grocery-anchored, including by Publix, Harris Teeter, and Kroger, increasing Brixmor's exposure to leading operators, and is located entirely within Brixmor's existing footprint, strengthening its position in high-conviction markets.

- Enhancing Brixmor's visible multi-year growth profile: The portfolios have meaningful occupancy and mark-to-market opportunities, with in-place rents averaging 32 percent less than Brixmor's current portfolio. In addition, Brixmor has identified approximately $100 million of redevelopment and outparcel development opportunities within the Brixmor Portfolio, including several potential Publix redevelopment projects, consistent with one of Brixmor's core value-creation capabilities. The portfolios are projected to generate long-term NOI growth consistent with Brixmor's stated long-term growth expectation of 4%.

- Growing and leveraging Brixmor's operating platform at scale: The transaction leverages Brixmor's national infrastructure, operating expertise, and retailer relationships to unlock value through leasing and operational initiatives. In addition, the joint venture is expected to generate attractive recurring fee income, including asset management, property management, and leasing fees. The joint venture will also create a potential pipeline of future acquisition opportunities for Brixmor.

- Generating immediate earnings accretion with balance sheet discipline: The transaction is expected to be immediately accretive to Brixmor's Nareit FFO per share. The capital efficient structure is consistent with Brixmor's commitment to maintaining a strong investment-grade balance sheet, while preserving capacity for future investment opportunities.

RBC Capital Markets, LLC is acting as lead financial advisor and Wells Fargo Securities is acting as a financial advisor to Brixmor and to the joint venture entity formed by Brixmor and Everview for purposes of the transaction. Cushman & Wakefield is acting as real estate advisor, and Hogan Lovells Cadwalader US LLP is acting as legal counsel to Brixmor. Simpson Thacher & Bartlett LLP is acting as legal advisor to Everview. Davies Ward Phillips & Vineberg LLP is acting as Canadian counsel for Brixmor and Everview. Royal Bank of Canada has provided Brixmor with a bridge commitment to fully fund Brixmor's required capital for the transaction for both the Brixmor Portfolio and Joint Venture Portfolio. Wells Fargo Bank, N.A., as Administrative Agent, and Royal Bank of Canada have provided a debt commitment to the joint venture. Wells Fargo Securities and Royal Bank of Canada will serve as Joint Bookrunners for the joint venture financing.

CONFERENCE CALL AND PRESENTATION INFORMATION

Brixmor will host a teleconference today, September 28, 2026 at 8:30 AM ET to discuss the transaction. To participate, please dial 877.704.4453 (domestic) or 201.389.0920 (international) within 15 minutes of the scheduled start of the call. The teleconference can also be accessed via a live webcast at https://www.brixmor.com in the Investors section. A replay of the teleconference will be available through October 12, 2026 by dialing 844.512.2921 (domestic) or 412.317.6671 (international) (Passcode: 13762791) or via the web through September 28, 2027 at https://www.brixmor.com in the Investors section.

A Presentation with additional details will be posted at https://www.brixmor.com in the Investors section.

ABOUT BRIXMOR PROPERTY GROUP

Brixmor (NYSE: BRX) owns and operates a high-quality, national portfolio of open-air shopping centers. Brixmor's 346 retail centers comprise approximately 63 million square feet of prime retail space in established trade areas. Brixmor's properties reflect its vision "to be the center of the communities we serve" and are home to a diverse mix of thriving national, regional, and local retailers. Brixmor is a valued partner to a broad range of retailers, including The TJX Companies, The Kroger Co., Publix Super Markets and Ross Stores.

Brixmor announces material information to its investors in SEC filings and press releases and on public conference calls, webcasts and the "Investors" page of its website at https://www.brixmor.com. Brixmor also uses social media to communicate with its investors and the public, and the information Brixmor posts on social media may be deemed material information. Therefore, Brixmor encourages investors and others interested in Brixmor to review the information that it posts on its website and on its social media channels.

ABOUT EVERVIEW PARTNERS

Everview Partners, L.P. is a private investment management firm founded in 2024 on the belief that applying both private equity and credit expertise to real asset investments could yield enduring performance across market cycles. Everview invests across the capital structure in real asset companies and properties and seeks to partner with talented business leaders to drive sustainable growth and profitability. For more information, please visit www.everviewcap.com.

ABOUT ADIA

Established in 1976, the Abu Dhabi Investment Authority (ADIA) is a globally-diversified investment institution that prudently invests funds on behalf of the Government of Abu Dhabi through a strategy focused on long-term value creation. For more information: https://www.adia.ae.

A New Sandwich From the Real Louisiana Kitchen, THAT Chicken from Popeyes, Buttermilk Biscuit and Sweet Honey Sauce Come Together in One Bold Menu Item

MIAMI, Sept. 28, 2026 /PRNewswire/ -- As a Real Louisiana Kitchen, Popeyes® doesn't just serve bold flavor, it's the authority on it. Popeyes' culinary team is always looking for new ways to bring bold flavors together, and they saw an opportunity to combine some of the menu's most beloved staples in an entirely new way. It's no surprise fans have long found their own ways to combine the brand's signature chicken and biscuits with honey on social media; but now, Popeyes is putting its culinary expertise behind that same craving, transforming it into their newest sandwich innovation, perfect for any meal of the day, available beginning September 28.

The Honey Chicken Biscuit is a simple, yet bold innovation: THAT Chicken from Popeyes on a larger version of our iconic buttermilk biscuit, paired with two sachets of sweet honey sauce, all for just $5.* A recipe that could only come from a Real Louisiana Kitchen. This sandwich brings Popeyes bold flavor and culinary credentials into a delicious, handheld bite, balancing crunchy and soft, savory and sweet, in a combination true to the brand's Louisiana roots. This is signature menu innovation at its heart, proof that some of the biggest ideas come from reimagining what's already cooking in our kitchens.

"At Popeyes, quality and bold flavor guide everything we do, and we're always looking for new ways to bring our most iconic items together," said Matt Rubin, Popeyes Chief Marketing Officer. "The Honey Chicken Biscuit is exactly that: our craveable chicken, our iconic buttermilk biscuit, and sweet honey sauce, crafted into one new sandwich. It's simple, it's unmistakably Popeyes, and it shows the kind of culinary care that turns flavors people already love into something entirely new."

The Honey Chicken Biscuit arrives on the heels of "THAT Chicken from Popeyes," the brand's new national campaign celebrating the bold flavor, handcrafted preparation and unmistakable generosity that have made Popeyes chicken iconic for more than 50 years. Popeyes isn't just celebrating THAT Chicken from Popeyes, they're finding even more craveable ways to serve it to their loyal guests.

The new Honey Chicken Biscuit will be available at participating Popeyes restaurants, the Popeyes app, and Popeyes.com nationwide beginning September 28 for $5.*

*Price may vary.

ABOUT POPEYES®

Founded in New Orleans in 1972, Popeyes® has over 50 years of history and culinary tradition. Popeyes® distinguishes itself with a unique New Orleans style menu featuring fried chicken, chicken tenders, fried shrimp, and other regional items. The chain's passion for its Louisiana heritage and flavorful authentic food has allowed Popeyes® to become one of the world's largest chicken quick service restaurants with over 4,000 restaurants in the U.S. and around the world. To learn more about the brand, please visit the Popeyes® brand website at Popeyes.com or follow us on Facebook, X, and Instagram.

SOURCE Popeyes

Share this article

Teleste Brings Live OTT Streams to Broadcast TV with New Luminato 4X4 Receiver

Operators can bring live OTT streams to sites that cannot use them directly-expanding service options for existing customers and opening new locations to TV delivery.

TURKU, Finland, Sept. 28, 2026 /PRNewswire/ -- Teleste today announced a new receiver for Luminato 4X4 that enables operators to deliver over-the-top (OTT) television streams to sites using conventional cable or IPTV distribution. Available in Q4 2026, the receiver converts incoming OTT streams into the formats those local systems require. By adding the Luminato receiver, operators can extend their television offering without changing their delivery network or the site's television distribution.

The new capability gives operators another way to use their OTT delivery infrastructure: the same live streams used to serve streaming customers can also supply a conventional television channel lineup at the destination. Delivery over broadband connections allows operators to serve locations beyond their own network. Hotels, hospitals, care facilities and multi-dwelling properties are natural applications, alongside other sites requiring local cable or IP television distribution.

"Moving the incoming television feed to streaming does not mean every screen has to become a streaming device," said Julius Tikkanen, Vice President, Video Service Platforms at Teleste. "Luminato handles that transition at the receiving site. Operators can develop their delivery network while continuing to offer television in the format that works for each customer."

Streaming reception with broadcast processing

The adaptive bitrate (ABR) receiver supports live MPEG-DASH streams and decryption of content protected by Widevine DRM. MPEG-DASH is a standard for delivering OTT television streams over broadband. The receiver converts these services into MPEG transport streams for local IP multicast or QAM distribution. IP and QAM outputs can operate simultaneously, allowing the same installation to serve different distribution requirements.

For cable distribution, the dense QAM module supports up to 32 QAM carriers per module, with support for DVB-C and ITU-T J.83 Annex B. Reception and output modules can be selected to match the installation's requirements. The Luminato 4X4 chassis accommodates up to six hot-swappable modules and dual power supplies, providing capacity for expansion, modular servicing and power redundancy.

The receiver will be available for both new Luminato 4X4 systems and compatible existing installations. New deployments can be configured for ABR reception from the outset. Existing users can add the receiver while retaining applicable processing and output modules. Both approaches draw on the same modular broadcast platform and its established range of IP and RF delivery options.

About Teleste

Teleste (HEL: TLT1V) offers an integrated portfolio of products and services that helps build and run a better-networked society. Our solutions deliver broadband and television services, enhance safety in public places, and support the use of public transport. With solid industry expertise and a strong drive for innovation, we are a leading international company in broadband, security and information technologies and related services. We connect with our customers through a global network of offices and partners. Teleste is listed on Nasdaq Helsinki. For more information, please visit www.teleste.com.

Media inquiries

Teleste - Linda Kallas, SVP, Communications, [email protected]

This information was brought to you by Cision http://news.cision.com

Share this article

TIANJIN, China, Sept. 28, 2026 /PRNewswire/ -- September 25–27, MHTE 2026 was held in Ulaanbaatar. Perennial General Hospital Tianjin, together with Tianjin Hospital, Tianjin Chest Hospital, and Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, formed a medical delegation to attend under the theme "International Diagnosis and Treatment • Tianjin Solutions — Building a Health Bridge on the China-Mongolia-Russia Economic Corridor."

Perennial General Hospital Tianjin is China's first wholly foreign-owned tertiary general hospital. Located in Tianjin Perennial Health City, the world's first medical, rehabilitation, eldercare, wellness, and cultural tourism high-speed rail TOD complex, it covers general hospitals, rehabilitation hospitals, brain hospitals, large health communities, and hotel clusters, committed to building an international, high-standard, full-cycle healthcare service platform. It has treated over 500 international patients from 41 countries and regions, including many from Mongolia.

This roadshow focuses on direct doctor-to-doctor exchanges, establishing specialty connections through academic lectures, case discussions, and second opinions, and provides Mongolian patients with evaluation, treatment, and follow-up support for seeking medical care in Tianjin, gradually forming a sustainable cross-border diagnosis and treatment channel. The expert delegation also held talks with Mongolian Trade and Development Bank, IWFCI Mongolia Chapter, and other institutions to explore group health checkups and follow-up specialty care cooperation models.

For more information, please visit: https://www.perennialgeneralhospital.com.cn/

Share this article

MOYOM Biotech Secures Financing from Cathay Capital to Accelerate Global Growth in Regenerative Aesthetics

SHANGHAI, Sept. 28, 2026 /PRNewswire/ -- MOYOM Biotech, a biotechnology company specializing in regenerative aesthetic biomaterials, today announced that it has completed a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital. The investment marks an important milestone in the company's development and will support its next phase of global growth.

The fund was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government to foster innovation in beauty, health and skin science. Cathay Capital has built a global investment ecosystem spanning consumer, healthcare and technology, with notable investments including Moonshot AI (Kimi), autonomous driving company Momenta, U.S. fintech company Chime, digital asset platform Ledger, global delivery platform Glovo and AI biotechnology company Owkin.

In addition to identifying emerging brands, investment platforms of this kind can give strategic partners earlier access to emerging technologies, supply-chain capabilities and innovation in adjacent industries. Cathay Capital's investment in MOYOM reflects growing interest in technologies and biomaterial innovations with the potential to shape the next generation of the beauty and medical aesthetics industry.

Founded in 2018, MOYOM focuses on nanomedical biomaterials and Class III absorbable implantable medical devices, particularly calcium hydroxylapatite (CaHA) regenerative materials. Its flagship brand, Aphranel®, brings MOYOM's proprietary biomaterials research to market. Positioned as a new-generation CaHA biostructurer, Aphranel® is designed to combine immediate structural support, regenerative stimulation and complete biodegradation.

MOYOM's technology platform is built around two proprietary technologies: ACD-MT® raspberry-shaped through-hole CaHA microspheres and PCD-ETT® physically cross-linked CMC gel technology. Together, they are engineered to deliver structural performance, support regenerative interaction and enable controlled biodegradation.

Aphranel® received Class III medical device registration from China's National Medical Products Administration (NMPA) in February 2025 and certification under the European Union Medical Device Regulation (EU MDR) in May 2026, establishing a regulatory foundation for international expansion. Since its commercial launch in May 2025, Aphranel® has been introduced in more than 700 medical aesthetics clinics across China, demonstrating increasing market adoption alongside continued scientific and regulatory progress.

With its proprietary technology platform, key regulatory milestones and growing market presence, MOYOM is entering a new phase of growth. Leveraging Cathay Capital's global ecosystem, the company plans to accelerate clinical translation, pursue additional regulatory approvals and expand into overseas markets, while continuing to invest in next-generation regenerative biomaterials.

The financing will support MOYOM's efforts to bring biomaterial innovation originating in China to international markets and establish Aphranel® as a science-driven regenerative aesthetics brand with global reach.

About MOYOM Biotech

Founded in 2018, MOYOM Biotech develops regenerative aesthetic biomaterials and absorbable implantable medical devices. The company developed Aphranel®, its flagship CaHA-based regenerative aesthetics brand.

SOURCE MOYOM Biotech

Share this article

CALGARY, AB, Sept. 28, 2026 /PRNewswire/ -- High Tide Inc. ("High Tide" or the "Company") (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), the high-impact, retail-forward enterprise built to deliver real-world value across every component of cannabis, announced today that it placed No. 315 out of 375 companies listed on the 2026 Report on Business ranking of Canada's Top Growing Companies, with a verified three-year revenue growth rate of 66% over the 2022 to 2025 measurement period. Highlighting the Company's increasing profitability profile, Adjusted EBITDA was also up 161% during this period.1

_______________________

1 Adjusted EBITDA is a non-IFRS financial measure

"Six consecutive years on this list is a milestone our entire team should be proud of. We have grown Canna Cabana into Canada's largest cannabis retail chain, built a deeply loyal customer base and more than doubled Adjusted EBITDA over the three-year period measured. We have done it by staying focused on value for our customers and disciplined execution across the business," said Raj Grover, Founder and Chief Executive Officer of High Tide.

"The business is moving with even greater momentum today. Following our strongest quarter yet, we are approaching an $800 million annualized revenue run rate, while Remexian is adding a significant new source of growth in Germany. With a strong foundation, a proven growth strategy and significant opportunities ahead, we are more energized than ever about the next phase of High Tide's growth. As always, I extend my deepest gratitude to our entire team, our ELITE and Cabana Club members, and our shareholders for their continued support," added Mr. Grover.

Canada's Top Growing Companies is an editorial ranking that was launched in 2019 to celebrate the achievements of innovative businesses in Canada. To qualify for this voluntary program, companies had to complete an in-depth application process and fulfill revenue requirements. In total, 375 companies earned a spot on this year's ranking. The full list of 2026 winners along with editorial coverage is published in the October issue of Report on Business magazine. The list is also published online here.

ABOUT HIGH TIDE

High Tide Inc. is the leading community-grown, retail-forward cannabis enterprise engineered to unleash the full value of the world's most powerful plant. Its wholly owned subsidiary, Canna Cabana, is the second-largest cannabis retail brand globally. High Tide (HITI) is uniquely-built around the cannabis consumer, with wholly-diversified and fully-integrated operations across all components of cannabis, including:

Retail: Canna Cabana™ is the largest cannabis retail chain in Canada, with 232 domestic and 1 international location. The Company's Canadian bricks-and-mortar operations span British Columbia, Alberta, Saskatchewan, Manitoba, and Ontario. Excluding British Columbia, where store counts are capped at 8, the Company holds a growing 14% share of the market. In 2021, Canna Cabana became the first cannabis discount club retailer in the world. In 2025, the Company became the first North American cannabis operator to launch a bricks-and-mortar presence in Germany. The Company also owns and operates multiple global e-commerce platforms offering accessories and hemp-derived products.

Medical Cannabis Distribution: Remexian Pharma GmbH is a leading German pharmaceutical company, with a 10.5% share of the German medical cannabis market, built for the purpose of importation and wholesale of medical cannabis products at affordable prices. Among all German medical cannabis procurers, Remexian has one of the most diverse reaches across the globe and is licensed to import from 22 countries including Canada.

High Tide consistently moves ahead of the currents, having been named one of Canada's Top Growing Companies by the Globe and Mail's Report on Business in 2026 for the sixth consecutive year and was recognized as a top 50 company by the TSX Venture Exchange (the "TSXV") in 2022, 2024 and 2025. High Tide was also ranked number one in the retail category on the Financial Times list of Americas' Fastest Growing Companies for 2023. To discover the full impact of High Tide, visit www.hightideinc.com. For investment performance, don't miss the High Tide profile pages on SEDAR+ and EDGAR.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws. Forward-looking information in this press release includes, but is not limited to, statements regarding the Company's expectations concerning the continued growth and development of its Canadian retail cannabis operations and German medical cannabis distribution business, the continued strengthening of Canna Cabana's position in Canada, the continued scaling of Remexian's operations in Germany and the Company's future growth and operating performance.

Forward-looking information is based on the Company's current expectations, estimates, projections, assumptions and beliefs as of the date of this press release. Material assumptions include assumptions regarding continued consumer demand for the Company's products and services; the Company's ability to maintain and expand its retail and distribution operations; the performance of Canna Cabana and Remexian; the availability of product supply; the Company's ability to retain required licences and regulatory authorizations; prevailing competitive, economic and market conditions; and the absence of material adverse changes in applicable laws or the Canadian and German cannabis markets.

Forward-looking information is subject to known and unknown risks and uncertainties that may cause actual results, performance or achievements to differ materially from those expressed or implied by such information. These risks and uncertainties include, among others, changes in consumer demand; competition; changes in cannabis laws, regulations or licensing requirements in Canada or Germany; the Company's ability to execute its growth strategy; supply-chain disruption; the availability and cost of capital; inflationary and other cost pressures; foreign exchange fluctuations; the performance and integration of acquired businesses; and the other risks described under the heading "Non-Exhaustive List of Risk Factors" in Schedule A to our current annual information form and in the Company's other continuous disclosure filings available under its profile on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.

Readers are cautioned not to place undue reliance on forward-looking information. Although the Company believes that the expectations and assumptions reflected in such information are reasonable, there can be no assurance that they will prove to be correct. The forward-looking information in this press release speaks only as of the date of this press release. The Company undertakes no obligation to update or revise such information to reflect new events or circumstances, except as required by applicable law.

CONTACT INFORMATION

Media Inquiries

Omar Khan

Chief Communications and Public Affairs Officer

High Tide Inc.

[email protected]

403-770-3080

Investor Inquiries

Vahan Ajamian

Capital Markets Advisor

High Tide Inc.

[email protected]

SOURCE High Tide Inc.

Share this article

The trade underlines the important role of Argus differential assessments in west African crude price discovery and the market's drive for greater transparency

LONDON, Sept. 28, 2026 /PRNewswire/ -- Oil traders have initiated the first west African (WAF) crude cargo transaction on the Argus Open Markets® (AOM®) platform, marking a significant step forward in the development of more transparent, auditable and efficient price discovery for physical crude markets.

The deal was initiated on the WAF crude AOM stack. TotalEnergies accepted the offer of a Nigerian Qua Iboe crude cargo at a premium of $4.10/bl to Dated Brent for a 950,000 bl cargo. The deal represents an estimated value of more than $115mn.

Global energy and commodity price reporting agency Argus operates AOM platforms across a range of markets, enabling registered participants to post bids and offers, discover counterparties and initiate transactions within a transparent and auditable framework.

This first deal builds on growing industry engagement with the west African crude AOM platform, where major producers, traders and refiners have increasingly used the screen to show value, test liquidity and contribute observable information to the Argus price assessment process.

West African grades are usually traded as differentials to other outright-price crude benchmarks, making robust, trusted and accurate differential assessments critical to commercial decision-making. Argus' west African crude differentials are widely referenced by market participants seeking to understand the relative value of Nigerian, Angolan and other regional grades in an increasingly competitive Atlantic basin market.

Historically, much of the physical crude market has relied on bilateral negotiations, which can make price discovery fragmented and difficult. AOM has the potential to change that by bringing bids, offers and trade initiation into a single visible venue, while preserving the bilateral nature of physical negotiations and allowing companies to help shape the value of important regional crude differentials in real time.

Argus Media chairman and chief executive Adrian Binks said: "The first initiated WAF crude trade on the Argus Open Markets platform is an important milestone for price discovery and comes as west African crude is increasingly in demand in markets both east and west of the region, as buyers seek alternatives for lost Mideast Gulf supplies. West African crude differentials are central to how the market prices and compares different grades, and we are pleased to support market participants with a transparent, auditable platform that complements Argus' long-established assessment process. This transaction underlines the industry's appetite for greater transparency and reinforces the important role Argus plays in bringing robust price information to global crude markets."

Argus contact information

London: Seana Lanigan

+44 20 7780 4200

Email Seana

Houston: Elizabeth Frye

+1 713 968 0000

Email Elizabeth

Singapore: Tomoko Hashimoto

+65 6496 9960

Email Tomoko

About Argus Media

Argus is the leading independent provider of market intelligence to the global energy and commodity markets. We offer essential price assessments, news, analytics, consulting services, data science tools and industry conferences to illuminate complex and opaque commodity markets.

Headquartered in London with over 1,500 staff, Argus is an independent media organisation with 32 offices in the world's principal commodity trading hubs.

Companies, trading firms and governments in 160 countries around the world trust Argus data to make decisions, analyse situations, manage risk, facilitate trading and for long-term planning. Argus prices are used as trusted benchmarks around the world for pricing transportation, commodities and energy.

Founded in 1970, Argus remains a privately held UK-registered company owned by employee shareholders and global growth equity firm General Atlantic.

Trademark notices

ARGUS, the Argus Logo, ARGUS MEDIA and ILLUMINATING THE MARKETS, Argus publication titles and index names are trademarks of Argus Media Limited. Visit Trademarks for more information.

SOURCE Argus Media

Share this article